• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution.呼吸道合胞病毒融合糖蛋白纳米颗粒疫苗在溶液中的结构特征和建模。
Mol Pharm. 2021 Jan 4;18(1):359-376. doi: 10.1021/acs.molpharmaceut.0c00986. Epub 2020 Dec 15.
2
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.呼吸道合胞病毒融合纳米颗粒疫苗免疫应答针对多个中和表位,有助于预防野生型和帕利珠单抗耐药突变病毒的挑战。
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
3
Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.作为呼吸道合胞病毒的母体疫苗的替代病毒样颗粒相关前融合 F 蛋白。
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00914-19. Print 2019 Dec 1.
4
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.呼吸道合胞病毒预融合(F)蛋白纳米颗粒疫苗:结构、抗原谱、免疫原性和保护作用。
Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12.
5
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.一种由稳定的嵌合型和复制缺陷型仙台病毒载体携带的呼吸道合胞病毒疫苗可保护小鼠,且不会引发疾病加重。
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.02298-16. Print 2017 May 15.
6
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.人类呼吸道合胞病毒:发病机制、免疫反应和当前疫苗方法。
Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6.
7
A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.一种嵌合糖蛋白与联合佐剂联合配制,可诱导针对人呼吸道合胞病毒和副流感病毒 3 型的保护性免疫。
Antiviral Res. 2018 Oct;158:78-87. doi: 10.1016/j.antiviral.2018.07.021. Epub 2018 Jul 30.
8
Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.呈现呼吸道合胞病毒融合或附着糖蛋白的混合病毒样颗粒诱导的附加保护作用。
Antiviral Res. 2014 Nov;111:129-35. doi: 10.1016/j.antiviral.2014.09.005. Epub 2014 Sep 18.
9
The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.呼吸道合胞病毒(RSV)G 蛋白增强包膜病毒样颗粒疫苗候选物中 RSV F 蛋白的免疫应答。
J Virol. 2023 Jan 31;97(1):e0190022. doi: 10.1128/jvi.01900-22. Epub 2023 Jan 5.
10
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.由F糖蛋白的融合后和融合前构象组成的新型呼吸道合胞病毒样颗粒疫苗。
Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.

引用本文的文献

1
All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?所有目光都聚焦在预融合稳定的F结构上,但我们是否忽略了呼吸道合胞病毒疫苗设计中替代靶点的潜力?
Vaccines (Basel). 2024 Jan 18;12(1):97. doi: 10.3390/vaccines12010097.
2
The road to approved vaccines for respiratory syncytial virus.呼吸道合胞病毒获批疫苗之路。
NPJ Vaccines. 2023 Sep 25;8(1):138. doi: 10.1038/s41541-023-00734-7.
3
The RSV F p27 peptide: current knowledge, important questions.呼吸道合胞病毒融合蛋白p27肽:当前认知与重要问题
Front Microbiol. 2023 Jun 21;14:1219846. doi: 10.3389/fmicb.2023.1219846. eCollection 2023.
4
The Efficiency of p27 Cleavage during Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent.呼吸道合胞病毒(RSV)感染期间 p27 裂解的效率依赖于细胞系和 RSV 亚型。
J Virol. 2023 May 31;97(5):e0025423. doi: 10.1128/jvi.00254-23. Epub 2023 May 3.
5
Nanoparticle-Based Bivalent Swine Influenza Virus Vaccine Induces Enhanced Immunity and Effective Protection against Drifted H1N1 and H3N2 Viruses in Mice.基于纳米颗粒的二价猪流感病毒疫苗诱导增强的免疫应答,并有效预防小鼠中 drifted H1N1 和 H3N2 病毒感染。
Viruses. 2022 Nov 3;14(11):2443. doi: 10.3390/v14112443.
6
Small-angle neutron scattering contrast variation studies of biological complexes: Challenges and triumphs.小角中子散射对比变化研究生物复合物:挑战与成功。
Curr Opin Struct Biol. 2022 Jun;74:102375. doi: 10.1016/j.sbi.2022.102375. Epub 2022 Apr 28.
7
Nanotechnology Fundamentals Applied to Clinical Infectious Diseases and Public Health.应用于临床传染病与公共卫生的纳米技术基础
Open Forum Infect Dis. 2021 Nov 20;8(12):ofab583. doi: 10.1093/ofid/ofab583. eCollection 2021 Dec.

本文引用的文献

1
Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.母亲接种 RSV 融合糖蛋白疫苗可显著保护新生狨猴免受呼吸道合胞病毒肺部攻击。
Vaccine. 2020 Jan 29;38(5):1258-1270. doi: 10.1016/j.vaccine.2019.11.003. Epub 2019 Nov 21.
2
Negative-Stain Transmission Electron Microscopy of Molecular Complexes for Image Analysis by 2D Class Averaging.用于二维分类平均图像分析的分子复合物负染色透射电子显微镜技术
Curr Protoc Microbiol. 2019 Sep;54(1):e90. doi: 10.1002/cpmc.90.
3
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.呼吸道合胞病毒预融合(F)蛋白纳米颗粒疫苗:结构、抗原谱、免疫原性和保护作用。
Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12.
4
Transient opening of trimeric prefusion RSV F proteins.三聚体 RSV F 蛋白的瞬时开放。
Nat Commun. 2019 May 8;10(1):2105. doi: 10.1038/s41467-019-09807-5.
5
Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis.2015 年全球老年人呼吸道合胞病毒相关急性呼吸道感染疾病负担估计:系统评价和荟萃分析。
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583. doi: 10.1093/infdis/jiz059.
6
Immunological basis for enhanced immunity of nanoparticle vaccines.纳米颗粒疫苗增强免疫的免疫学基础。
Expert Rev Vaccines. 2019 Mar;18(3):269-280. doi: 10.1080/14760584.2019.1578216. Epub 2019 Feb 14.
7
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.呼吸道合胞病毒融合纳米颗粒疫苗免疫应答针对多个中和表位,有助于预防野生型和帕利珠单抗耐药突变病毒的挑战。
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
8
RSV prophylaxis in premature infants.早产儿呼吸道合胞病毒预防
Minerva Pediatr. 2018 Dec;70(6):579-588. doi: 10.23736/S0026-4946.18.05300-8. Epub 2018 Oct 18.
9
Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F Subunit Are Critical for Its Fusion Activity.呼吸道合胞病毒融合蛋白 F 亚基的顶端环中的五个残基对其融合活性至关重要。
J Virol. 2018 Jul 17;92(15). doi: 10.1128/JVI.00621-18. Print 2018 Aug 1.
10
Designing and Performing Biological Solution Small-Angle Neutron Scattering Contrast Variation Experiments on Multi-component Assemblies.设计和执行多组分组装体的生物溶液小角中子散射对比变化实验。
Adv Exp Med Biol. 2017;1009:65-85. doi: 10.1007/978-981-10-6038-0_5.

呼吸道合胞病毒融合糖蛋白纳米颗粒疫苗在溶液中的结构特征和建模。

Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution.

机构信息

NIST Center for Neutron Research, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States.

Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878, United States.

出版信息

Mol Pharm. 2021 Jan 4;18(1):359-376. doi: 10.1021/acs.molpharmaceut.0c00986. Epub 2020 Dec 15.

DOI:10.1021/acs.molpharmaceut.0c00986
PMID:33322901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10467610/
Abstract

The respiratory syncytial virus (RSV) fusion (F) protein/polysorbate 80 (PS80) nanoparticle vaccine is the most clinically advanced vaccine for maternal immunization and protection of newborns against RSV infection. It is composed of a near-full-length RSV F glycoprotein, with an intact membrane domain, formulated into a stable nanoparticle with PS80 detergent. To understand the structural basis for the efficacy of the vaccine, a comprehensive study of its structure and hydrodynamic properties in solution was performed. Small-angle neutron scattering experiments indicate that the nanoparticle contains an average of 350 PS80 molecules, which form a cylindrical micellar core structure and five RSV F trimers that are arranged around the long axis of the PS80 core. All-atom models of full-length RSV F trimers were built from crystal structures of the soluble ectodomain and arranged around the long axis of the PS80 core, allowing for the generation of an ensemble of conformations that agree with small-angle neutron and X-ray scattering data as well as transmission electron microscopy (TEM) images. Furthermore, the hydrodynamic size of the RSV F nanoparticle was found to be modulated by the molar ratio of PS80 to protein, suggesting a mechanism for nanoparticle assembly involving addition of RSV F trimers to and growth along the long axis of the PS80 core. This study provides structural details of antigen presentation and conformation in the RSV F nanoparticle vaccine, helping to explain the induction of broad immunity and observed clinical efficacy. Small-angle scattering methods provide a general strategy to visualize surface glycoproteins from other pathogens and to structurally characterize nanoparticle vaccines.

摘要

呼吸道合胞病毒(RSV)融合(F)蛋白/聚山梨醇酯 80(PS80)纳米颗粒疫苗是用于母体免疫接种和保护新生儿免受 RSV 感染的最具临床进展的疫苗。它由接近全长的 RSV F 糖蛋白组成,具有完整的膜结构域,与 PS80 去污剂配制成稳定的纳米颗粒。为了了解疫苗的功效的结构基础,对其结构和溶液中的流体力学性质进行了全面研究。小角中子散射实验表明,纳米颗粒含有平均 350 个 PS80 分子,形成圆柱形胶束核心结构和 5 个 RSV F 三聚体,它们围绕 PS80 核心的长轴排列。全长 RSV F 三聚体的全原子模型是根据可溶性外域的晶体结构构建的,并围绕 PS80 核心的长轴排列,从而生成与小角中子和 X 射线散射数据以及透射电子显微镜(TEM)图像一致的构象集合。此外,发现 RSV F 纳米颗粒的流体力学尺寸可通过 PS80 与蛋白质的摩尔比来调节,这表明纳米颗粒组装的机制涉及 RSV F 三聚体的添加和沿着 PS80 核心的长轴生长。该研究提供了 RSV F 纳米颗粒疫苗中抗原呈递和构象的结构细节,有助于解释广泛免疫的诱导和观察到的临床疗效。小角度散射方法为可视化其他病原体的表面糖蛋白和结构表征纳米颗粒疫苗提供了一种通用策略。